Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
193,828,463
-
Total 13F shares
-
184,964,449
-
Share change
-
-3,594,507
-
Total reported value
-
$9,606,990,497
-
Put/Call ratio
-
16%
-
Price per share
-
$51.94
-
Number of holders
-
388
-
Value change
-
-$158,354,676
-
Number of buys
-
217
-
Number of sells
-
172
Institutional Holders of BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) as of Q3 2025
As of 30 Sep 2025,
BridgeBio Pharma, Inc. - Common Stock, par value $0.001 per share (BBIO) was held by
388 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
184,964,449 shares.
The largest 10 holders included
VANGUARD GROUP INC, VIKING GLOBAL INVESTORS LP, BlackRock, Inc., Kohlberg Kravis Roberts & Co. L.P., JANUS HENDERSON GROUP PLC, FARALLON CAPITAL MANAGEMENT LLC, Aisling Capital Management LP, STATE STREET CORP, Invesco Ltd., and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
388
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.